Sucampo Pharmaceuticals (SCMP) was Upgraded by WallachBeth to ” Buy” and the brokerage firm has set the Price Target at $16. Earlier the firm had a rating of “Hold ” on the company shares. WallachBeth advised their investors in a research report released on May 5, 2016.
Many Wall Street Analysts have commented on Sucampo Pharmaceuticals. Mizuho Upgraded Sucampo Pharmaceuticals on Apr 20, 2016 to ” Buy”, Price Target of the shares are set at $14.Shares were Reiterated by WallachBeth on Mar 10, 2016 to “Hold” and Lowered the Price Target to $ 16 from a previous price target of $27 .Company shares were Reiterated by Maxim Group on Mar 9, 2016 to “Buy”, Firm has raised the Price Target to $ 26 from a previous price target of $25 .
On the company’s financial health, Sucampo Pharmaceuticals reported $0.21 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on May 4, 2016. Analyst had a consensus of $0.19. The company had revenue of $47.20 million for the quarter, compared to analysts expectations of $44.05 million. The company’s revenue was up 60.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.14 EPS.
Sucampo Pharmaceuticals opened for trading at $10.9 and hit $11.16 on the upside on Wednesday, eventually ending the session at $10.74, with a gain of 0.47% or 0.05 points. The heightened volatility saw the trading volume jump to 5,65,378 shares. Company has a market cap of $489 M.
In a different news, on Nov 18, 2015, Andrew P Smith (CFO) purchased 1,605 shares at $17.03 per share price. According to the SEC, on Aug 31, 2015, Daniel P Getman (director) sold 30,000 shares at $28.14 per share price. On Mar 18, 2015, Anthony C. Celeste (director) sold 65,966 shares at $17.34 per share price, according to the Form-4 filing with the securities and exchange commission.
Sucampo Pharmaceuticals Inc. is a global biopharmaceutical company. The Company focuses on research and development of drugs to treat gastrointestinal ophthalmic and oncology-based inflammatory disorders. It generates revenue from product royalties development milestone payments product sales and clinical development activities. Its operations are conducted through Sucampo AG (SAG) based in Zug Switzerland through which the Company conducts certain worldwide and European operations; Sucampo Pharma LLC based in Tokyo and Osaka Japan through which the Company conducts its Asian operations; Sucampo Pharma Americas LLC based in Bethesda through which the Company conducts operations in North and South America and Sucampo Pharma Europe Ltd. based in Oxford United Kingdom. The Company’s geographic segments are Asia the Americas and Europe.